Drug Profile
MPL 5821
Alternative Names: ESM™-p38 MAPK inhibitor; MPL 5821Latest Information Update: 28 Jan 2022
Price :
$50
*
At a glance
- Originator Chroma Therapeutics
- Class Antineoplastics; Drug conjugates; Small molecules
- Mechanism of Action P38 mitogen-activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jan 2022 No recent reports of development identified for preclinical development in Cancer in United Kingdom
- 09 Jan 2020 MPL 5821 is still in preclinical trials for Cancer in the UK (Macrophage Therapeutics website, January 2020)
- 28 Jan 2019 No recent reports of development identified for preclinical development in Cancer in United Kingdom (PO)